Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kita, Y.
Right arrow Articles by Imada, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kita, Y.
Right arrow Articles by Imada, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1986) 17, 205-213
© 1986 The British Society for Antimicrobial Chemotherapy

research-article

Pharmacokinetics of SCE-1141, a stereoisomer of cefmenoxime, in rats

Yasuo Kita, Koichi Itakura, Kanji Tsuchiya and Akira Imada

Central Research Division, Takeda Chemical Industries, Ltd. 2–17–85, Jusohonmachi, Yodogawa-ku, Osaka 532, Japan

accepted 20 August 1985

The pharmacokinetic properties of SCE-1141, an anti stereoisomer of cefmenoxime, were compared with those of cefmenoxime. SCE-1141 levels in plasma and tissues peaked at 30 min after the intramuscular administration of 20 mg/kg; the plasma level declined with a half-life of about 18 min. The area under the concentration-time curve in plasma and the half-life after intravenous administration were similar to those after intramuscular administration. SCE-1141 was distributed at high concentrations in the liver and kidney of normal rats, and at lower concentrations in the liver of rats with acute liver impairment. SCE-1141 levels in plasma and tissues, except liver, were lower than those of cefmenoxime. The 24-h biliary and urinary excretions of SCE-1141 were 73% and 26% of the dose, respectively; these were significantly different from those of cefmenoxime: 33% in bile and 55% in urine. In rats with acute liver impairment, the biliary excretion of SCE-1141 was decreased, and the urinary excretion increased.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.